子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | Process for the preparation of cimetidine | US147423 | 1988-01-25 | US4855439A | 1989-08-08 | Teofil Zizek |
| A new and simple process for the preparation of crystalline cimetidine (N-cyano-N'-methyl-N"-{2/(5-methyl-1H-imidazole-4-yl)methylthio/ethyl}guanidine) is described, wherein cimetidine is obtained by reacting O-ethyl-S-(4-methylimidazolyl-5-methyl)dithiocarbonate hydrobromide with N-cyano-N'-methyl-N"-(2-chloroethyl)guanidine in an aqueous methylamine solution at a temperature between room temperature and the reflux temperature of the reaction mixture, whereupon the desired compound is separated.Cimetidine is a valuable drug in the therapy of the ulcer disease. | ||||||
| 162 | Naphthalene aminoalkylene ethers and thioethers, and their pharmaceutical uses | US489814 | 1983-04-29 | US4543352A | 1985-09-24 | Donald E. Kuhla; Henry F. Campbell; William L. Studt |
| A class of naphthalene aminoalkylene ether and thioether compounds exhibiting pharmacological activity including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions are disclosed. | ||||||
| 163 | Hair-growth promoting composition and usage thereof | US15769472 | 2016-10-18 | US11931325B2 | 2024-03-19 | Shohei Shinozaki; Kentaro Shimokado |
| Novel compositions that promote hair growth or hair restoration, and compositions that prevent hair loss. Compositions including an iNOS inhibitor as an active ingredient are provided. Advantageous affects for hair growth or hair restoration are obtained when a composition including an iNOS inhibitor as an active ingredient is administered to a mammal. For the iNOS inhibitor, a low-molecular compound, an antibody, or a nucleic acid drug such as an antisense oligonucleotide or siRNA may be used. A method of screening for effective substances for promotion of hair growth or hair restoration or prevention of hair loss is also provided. | ||||||
| 164 | Antiviral compounds and methods | US15262075 | 2016-09-12 | US10683263B2 | 2020-06-16 | Gary Dinneen Ewart; Wayne Morris Best |
| The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals. | ||||||
| 165 | Guanidine compounds for carbon dioxide capture | US15978323 | 2018-05-14 | US10583387B2 | 2020-03-10 | Radu Custelcean; Neil Justin Williams; Charles Aaron Seipp |
| A method for removing carbon dioxide from a gaseous source, the method comprising: (i) contacting said gaseous source with an aqueous solution of a carbon dioxide sorbent that reacts with carbon dioxide to form an aqueous-soluble carbonate or bicarbonate salt of said carbon dioxide sorbent; (ii) contacting the aqueous solution from step (i) with a bis-iminoguanidine carbon dioxide complexing compound, which is different from the carbon dioxide sorbent, to result in precipitation of a carbonate or bicarbonate salt of said carbon dioxide complexing compound and regeneration of the carbon dioxide sorbent; and (iii) removing the precipitated carbonate or bicarbonate salt from the aqueous solution in step (ii) to result in a solid form of said carbonate or bicarbonate salt of the carbon dioxide complexing compound. The method may further include a step (iv) of regenerating the carbon dioxide complexing compound by subjecting the precipitated salt to sufficient heat and/or vacuum. | ||||||
| 166 | Methods for encapsulation and microcapsules produced thereby | US15032731 | 2014-10-27 | US10478401B2 | 2019-11-19 | Elzbieta Gorecka; Jaroslaw Dziadek; Wojciech Ambroziak |
| The invention relates to methods for encapsulating a material comprising the steps of: (a) providing an aqueous solution or suspension of the material that is to be encapsulated, (b) warming the aqueous solution or suspension to a temperature that is sufficient to enable dissolution of a first biocompatible polymer in the aqueous solution or suspension without adversely affecting the properties of the material to be encapsulated, (c) dissolving the first biocompatible polymer in the aqueous solution or suspension, (d) de-aerating the solution or suspension obtained in step (c), (e) emulsifying the solution or suspension obtained in (d) in a biocompatible oil comprising a surfactant to create microdroplets, and (f) hardening the microdroplets by dropwise addition of an aqueous solution comprising Zn2+ ions and a second biocompatible polymer to form microcapsules; the invention further relates to microcapsules obtained by methods of the invention and their uses. | ||||||
| 167 | Azine metal phosphates as flame-retardant materials | US14436329 | 2012-10-16 | US09505793B2 | 2016-11-29 | Wolfgang Wehner |
| The present invention relates to azine metal phosphates, compositions containing the same, a process for preparing the same and their use as flame retardants. Typical representatives are (A-H)(+)[MtPO4](+).2H2O and (Mel-H)(+)[AlP2O7](+) (where A=melamine or guanidine, Mel=melamine and Mt=Mg or Zn). | ||||||
| 168 | Dendritic molecular intracellular transporters and methods of making and using same | US11844353 | 2007-08-23 | US08969622B2 | 2015-03-03 | Eva M. Harth; James E. Crowe, Jr.; Kui Huang; Sharon K. Hamilton; Heidi E. Hamm; Bryan Voss |
| In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | ||||||
| 169 | Forming spherical crystal habit | US13786715 | 2013-03-06 | US08962888B2 | 2015-02-24 | Dorin V. Preda; Prakash B. Joshi; Anait (Tsinberg) Scherer; Laurel A. Vernarelli |
| Methods for forming spherical crystal habit are shown. A needle-shaped crystal habit, a solvent, and a surfactant are combined and dissolved forming a first solution. The first solution and an anti-solvent are combined forming a second solution. The second solution is cooled. Spherical crystal habit is formed. | ||||||
| 170 | N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same | US13241731 | 2011-09-23 | US08541474B2 | 2013-09-24 | Sung Wuk Kim; Sung Soo Jun; Young Gwan Jo; Ja Seong Koo; Young Woong Kim |
| The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same. | ||||||
| 171 | Aryl guanidine F1F0-ATPase inhibitors and related methods | US13062741 | 2009-09-11 | US08497307B2 | 2013-07-30 | Gary D. Glick; Peter Toogood; Gina Ney |
| The invention provides to a family of aryl guanidine—based F1F0—ATPase inhibitors, e.g., mitochondrial F1F0—ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders. | ||||||
| 172 | Use of agents containing creatine, creatinine and/or their derivatives to fortify and improve the structure of keratinic fibers | US11839633 | 2007-08-16 | US08318676B2 | 2012-11-27 | Rudolf Bimczok; Thomas Kripp; Beate Grasser; Christian Springob |
| The invention relates to the use of creatine, creatinine and/or derivatives thereof and/or their salts in an agent for hardening, strengthening, restructuring or increasing the shine, volume or combability of keratin fibers, particularly of human hair. | ||||||
| 173 | Inhibition of sweat malodor | US11779462 | 2007-07-18 | US08206692B2 | 2012-06-26 | Christian Starkenmann; Anthony Clark; Myriam Troccaz; Yvan Niclass |
| The present invention relates to a method for screening compounds having the ability to prevent, treat or reduce malodor development on body surfaces. In particular, the method allows to efficiently screen for compound having the ability of preventing sweat malodor development caused by volatile sulfur compounds (VSCs). The present invention is based on the finding of the direct precursor of naturally VSCs, which is present in human sweat and which will be metabolized by Staphylococci to VSCs. | ||||||
| 174 | Process for the preparation of guanidinium salts | US10588190 | 2005-01-17 | US07439395B2 | 2008-10-21 | Nikolai (Mykola) Ignatyev; Urs Welz-Biermann; German Bissky; Helge Willner |
| The present invention relates to a two-step process for the preparation of guanidinium salts of the formula (1), where the substituents R have a meaning indicated in Claim, and A− is a sulfonate, alkyl- or arylsulfate, hydrogensulfate, imide, methanide, carboxylate, phosphate, phosphinate, phosphonate, borate, thiocyanate, perchlorate, fluorosilicate or nitrate, and to intermediate compounds from this process. | ||||||
| 175 | Carrier ampholytes of high pH range | US10763405 | 2004-01-21 | US07022214B2 | 2006-04-04 | Lee Olech |
| Carboxylic acid-substituted polyalkylene polyamines in which amine nitrogen atoms on the polyamine backbone structure are replaced by guanidine groups provide a pH range extending into high pH values. These substances are useful as carrier ampholytes in isoelectric focusing. | ||||||
| 176 | Compositions and dosage forms for enhanced absorption | US10978139 | 2004-10-29 | US20050165102A1 | 2005-07-28 | Patrick Wong; Dong Yan; George Guittard |
| Disclosed is controlled delivery of pharmaceutical agents and methods, dosage forms and devices therefore. In particular, formulation, dosage forms, methods and devices for enhanced absorption and controlled delivery drug compounds are disclosed. | ||||||
| 177 | Administration of levodopa and carbidopa | US10978252 | 2004-10-29 | US20050163850A1 | 2005-07-28 | Patrick Wong; Dong Yan; Stephen Hwang; George Guittard |
| Disclosed are substances, compositions, dosage forms and methods that comprise levodopa and/or carbidopa. | ||||||
| 178 | Compositions and dosage forms for enhanced absorption of iron | US10978137 | 2004-10-29 | US20050163849A1 | 2005-07-28 | Patrick Wong; Dong Yan; George Guittard |
| A complex comprised of iron and a transport moiety, such as a fatty acid, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of iron through a period of ten to twenty-four hours, thus enabling a true once-daily dosage form for iron. | ||||||
| 179 | Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin | US10978136 | 2004-10-29 | US20050163848A1 | 2005-07-28 | Patrick Wong; Dong Yan; George Guittard |
| A complex comprised of gabapentin or pregabalin and a transport moiety, such as an alkyl sulfate, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of the drug through a period of ten to twenty-four hours, thus enabling a once-daily dosage form for gabapentin or pregabalin. | ||||||
| 180 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | US11032297 | 2005-01-10 | US20050159457A1 | 2005-07-21 | Wenxi Pan; Tianbao Lu; Thomas Markotan; Bruce Tomczuk |
| Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi. | ||||||
QQ群二维码
意见反馈
意见反馈